BioMedNewsBreaks Archive - Page 204 of 221

ThursdayOct 15, 2020 1:58 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide its expertise in protein expression and solubility studies. A recent article discussing this quotes Soluble Biotech founder Dr. Larry DeLucas. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” Dr. DeLucas stated. “We quadrupled our laboratory and…

WednesdayOct 14, 2020 11:00 am

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data at the event hosted by the International Association for the Study of Lung Cancer. Per the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high-risk…

WednesdayOct 14, 2020 10:44 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary,…

TuesdayOct 13, 2020 1:05 pm

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) S-4 Registration Statement Declared Effective by SEC, to Hold Special Meeting of Shareholders

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that has signed a detailed merger agreement with 180 Life Sciences Corp., today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the registration statement on Form S-4 (File No. 333-234650) it filed relating to the previously announced business combination with 180 Life Sciences (the “Business Combination”). According to the update, the company has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the company’s stockholders to…

TuesdayOct 13, 2020 12:38 pm

BioMedNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX), Leading Cancer Charity Announce Encouraging Preliminary Phase 1 Study Results

Lineage Cell Therapeutics (NYSE American: LCTX) (TASE: LCTX) and Cancer Research UK have released encouraging results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (“NSCLC”). LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, worked together on the study, which focused on VAC2. Highlights of the study include potent induction of immune responses observed with the VAC2 vaccine and peripheral antigen-specific immunogenicity above 3% observed at multiple timepoints. In addition, VAC2 appeared to be well tolerated with…

TuesdayOct 13, 2020 12:12 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently,…

TuesdayOct 13, 2020 11:20 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. According to the update, Gateway Flex enables employers to personalize the health-care experience to meet the diverse and rapidly changing needs of their employees and allows employers to pay only for solutions in which their employees engage. “We believe that our inclusion in Vitality's Gateway Flex offering represents another recent validation of our digital therapeutic solution and reinforces our position as a partner of choice,” Rick Anderson, president and general…

MondayOct 12, 2020 12:58 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, on Friday announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. According to the update, application has been made for listing the common stock on the Nasdaq Capital Market under the ticker symbol “VVOS.” The proposed $20,000,000 offering (not including the underwriters’ over-allotment option), which is subject to market conditions with no assurance as to its actual completion or terms, has…

MondayOct 12, 2020 9:48 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment from The Balancing Act titled, "Behind the Mystery," which will air on Lifetime TV and focus on glioblastoma. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of CNS Pharmaceuticals’ Scientific Advisory Board. In addition, a re-airing of the segment is planned for October 23, 2020. "It is encouraging to…

FridayOct 09, 2020 12:11 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, was featured in a Simply Wall St article. The piece highlights PCSA Co-Founder Patrick Lin’s recent stock purchase at near current price. The article reads, “Potential Processa Pharmaceuticals Inc. (NASDAQ: PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) S-4 Registration Statement Declared Effective by SEC, to Hold Special Meeting of Shareholders

BioMedNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX), Leading Cancer Charity Announce Encouraging Preliminary Phase 1 Study Results

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search